Majors
101 IP cases indexed. Covers patent matters.
Cases Presided Over
101 cases indexed | Page 2 of 4
Alamar Biosciences, Inc. v.Olink Proteomics AB et al.
The petitioner failed to prove the obviousness of claims 1-20 of U.S. Patent No. 7883848 in a Final Written Decision. The Board adopted a specific claim construction for 'selecting all cis-reactive cells exhibiting the detectable trace,' defining it as selecting associations of at least two interactor moieties joined by an associated oligonucleotide that exhibit the detectable trace.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB found multiple claims unpatentable under both § 102 (anticipation) and § 103 (obviousness). The decision centered on the combination of prior art references—specifically Iafrate, Kivioja, and Bielas—in the context of Next Generation Sequencing (NGS) technologies. Claim construction was finalized, defining key terms like 'identifier site' and 'indexing site'.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB upheld the patent against IPR challenges related to NGS target enrichment. The Board clarified that 'enrichment' requires an increased proportion of the sequence relative to others, not just a raw increase in fragment count. Petitioner failed to meet its burden of proof on unpatentability.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB issued a final written decision rejecting all grounds of unpatentability asserted by the Petitioner regarding NGS target enrichment claims. The Board adopted the Patent Owner's narrow definition of 'enrichment,' finding that the prior art failed to teach the claimed proportional increase in target fragments.
Imperative Care, Inc. v.Inari Medical, Inc.
The Board found that the claims were obvious over prior art references by combining known features to achieve a predictable result. Despite initial disputes over claim construction, the Petitioner failed to provide sufficient motivation for combining specific prior art elements.
NEURENT MEDICAL INC. et al. v.The Foundry, LLC et al.
NEURENT MEDICAL INC. successfully petitioned PTAB for institution of IPR against THE FOUNDRY, LLC's nasal cavity treatment patent (11679077). The Board found sufficient evidence across multiple grounds of anticipation and obviousness to proceed to trial.
Encube Ethicals Pvt. Ltd. v.Dermavant Sciences GmbH et al.
Encube Ethicals successfully challenged Dermavant Sciences' patent claims in the PTAB, leading to institution of the case. The Board found sufficient grounds for anticipation (102) and obviousness (103), specifically regarding psoriasis treatment methods. This decision significantly strengthens Encube's position by validating their prior art arguments against the '088 patent.
Inari Agriculture, Inc. v.Corteva Agriscience LLC et al.
Inari Agriculture successfully petitioned to institute an IPR against Corteva Agriscience's GMO patents based on prior art from Barbour. The Board found a reasonable likelihood of prevailing regarding anticipation and obviousness over the cited publication, moving the case toward trial.
Imperative Care, Inc. v.INARI MEDICAL, INC.
Imperative Care, Inc. successfully challenged nine claims of INARI MEDICAL's hemostasis valve patent (11697011) at the PTAB. The Board found sufficient evidence for Petitioner’s anticipation challenge against Claim 1 after adopting a broad interpretation of the term 'filament.'
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB denied the institution of an IPR challenge against Inari Medical's patent (11744691) covering emboli treatment systems. The Board found that the petitioner, Imperative Care, Inc., failed to demonstrate a reasonable likelihood of prevailing on its grounds of anticipation and obviousness.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies successfully petitioned IPR against Tecan Genomics' NGS patent (US 10036012), showing a reasonable likelihood that prior art (Meyer) anticipates claims. The Board granted institution, setting the stage for a full trial on all 22 challenged claims.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies successfully challenged the '108 patent's claims in a PTAB institution decision, finding reasonable likelihood of prevailing on anticipation for Claim 1. The Board affirmed that prior art disclosure was sufficient to support the enrichment limitation using Meyer et al.
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully convinced the PTAB to institute trial proceedings against Tecan Genomics, Inc. regarding a high-throughput sequencing patent (11098357). The Board found reasonable likelihood that claims 1 through 10 are unpatentable under both anticipation (§ 102) and obviousness (§ 103).
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully petitioned to institute IPR proceedings against Tecan Genomics for patent number 11725241. The Board found sufficient evidence of unpatentability across multiple claims based on grounds of anticipation (35 U.S.C. § 102) and obviousness (35 U.S.C. § 103).
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully petitioned the PTAB against Tecan Genomics regarding claims related to Next-Generation Sequencing (NGS). The Board instituted review, finding a reasonable likelihood of prevailing on obviousness grounds.
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully petitioned to institute IPR proceedings against Tecan Genomics, challenging claims of U.S. Patent No. 10876108 based on obviousness (35 U.S.C. § 103). The Board found that the Examiner erred in relying solely on secondary considerations, adopting the Petitioner's view that combining Shapero and Delseny renders multiple claims obvious.
Garmin International, Inc. v.Cardiacsense LTD
Garmin International successfully navigated the initial stages of its IPR challenge against Cardiacsense LTD's '998 patent, establishing a reasonable likelihood of prevailing on several grounds. The Board found that certain claims were not entitled to an earlier effective filing date due to insufficient written description support for a compass feature in prior applications.
Imperative Care, Inc. v.Inari Medical, Inc.
Imperative Care challenges Inari Medical's hemostasis valve patent (11554005) on obviousness grounds. The PTAB instituted the IPR, requiring further review of claims 1-15 based on prior art combinations.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB decided to institute trial on all challenged claims of the '921 patent, despite preliminary evidence not supporting anticipation over Schaffer. The Board adopted a broad definition of 'filament' but ultimately found that the claim language required flexibility based on intrinsic and extrinsic teachings.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB institution decision in this IPR found that the petitioner met its burden of showing a reasonable likelihood of prevailing on at least claim 1. The dispute centers on obviousness (35 U.S.C. § 103) regarding medical devices used for aspirating clot material from blood vessels.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products, Inc.'s IPR petition against Solmetex, LLC's dental device patent was denied by the PTAB. The Board ruled that Petitioner failed to provide sufficient evidence regarding obviousness over prior art references like Black and Park/Baughan/Johnson.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies sought IPR of Tecan Genomics' patent covering nucleic acid technologies. The patent owner filed a terminal disclaimer of the entire patent, prompting the Board to grant an adverse judgment and terminate the proceeding.
QIAGEN Sciences, LLC v.Tecan Group AG
Tecan Group AG seeks Director Review to overturn the PTAB’s institution of QIAGEN’s IPR, arguing that parallel petitions create inefficiency and unfairness. The request cites statutory grounds under 35 U.S.C. § 316(b) and an Acting Director memo.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB denied Imperative Care’s petition to institute an IPR against Inari Medical’s U.S. Patent 11,744,691, finding no reasonable likelihood of success. The Board concluded the cited prior art did not disclose the required negative‑pressure pump configuration.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,011 B2 hemostasis valve patent after finding Imperative Care’s likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care’s petition to review Inari Medical’s 11,744,691 patent covering catheter‑based embolism removal. The Board found the petitioner had not shown a reasonable likelihood of prevailing on any of the 31 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s U.S. Patent 12,016,580 covering intravascular embolism treatment devices after finding Imperative Care’s obviousness arguments sufficiently promising.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation and obviousness over Schaffer and its combinations with Hartley, Eller, and Garrison.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted inter partes review on all fifteen claims of Inari Medical’s ’005 patent, finding Imperative Care’s obviousness arguments against the hemostasis valve features sufficiently plausible.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim. The dispute centers on the definition of “filament” and the applicability of Schaffer, Hartley, and Eller references.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.